These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18575908)

  • 1. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
    Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: Mortality and prognostic factors.
    Callejas-Díaz A; Fernández-Pérez C; Ramos-Martínez A; Múñez-Rubio E; Sánchez-Romero I; Vargas Núñez JA
    Med Clin (Barc); 2019 Feb; 152(3):83-89. PubMed ID: 29885868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
    Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and outcome of patients with community-acquired Pseudomonas aeruginosa bacteraemia.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Clin Microbiol Infect; 2005 May; 11(5):415-8. PubMed ID: 15819873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia.
    Cheong HS; Kang CI; Wi YM; Kim ES; Lee JS; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    Am J Med; 2008 Aug; 121(8):709-14. PubMed ID: 18691485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.
    Rojas A; Palacios-Baena ZR; López-Cortés LE; Rodríguez-Baño J
    Clin Microbiol Infect; 2019 Aug; 25(8):964-970. PubMed ID: 30995530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
    Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
    Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
    BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia.
    Cheong HS; Kang CI; Kwon KT; Heo ST; Wi YM; Kim ES; Lee JS; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    J Antimicrob Chemother; 2007 Dec; 60(6):1355-60. PubMed ID: 17923453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
    Lee CC; Lee CH; Hong MY
    Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
    Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset Escherichia coli, Klebsiella spp. and Proteus mirabilis bacteraemia.
    Hsieh CC; Lee CH; Hong MY; Hung YP; Lee NY; Ko WC; Lee CC
    Int J Antimicrob Agents; 2016 Dec; 48(6):712-718. PubMed ID: 27836382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
    Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome.
    Dantas RC; Ferreira ML; Gontijo-Filho PP; Ribas RM
    J Med Microbiol; 2014 Dec; 63(Pt 12):1679-1687. PubMed ID: 25261066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.
    Hattemer A; Hauser A; Diaz M; Scheetz M; Shah N; Allen JP; Porhomayon J; El-Solh AA
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3969-75. PubMed ID: 23733476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.
    Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Fattah MA; Haquin J; MacGowan A; Grier S; Chazan B; Yanovskay A; Ami RB; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Maurer S; Rodriguez-Bano J; Morales I; Oliver A; de Gopegui ER; Cano A; Machuca I; Gozalo-Marguello M; Martinez-Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
    Int J Antimicrob Agents; 2020 Feb; 55(2):105847. PubMed ID: 31770625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
    Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.